Key result
This review summarizes the mechanisms underlying the development of hypertriglyceridemia and its management, including emerging therapies targeted at specific molecular pathways.
Why the study?
Hypertriglyceridemia is common and poses a risk for cardiovascular disease and pancreatitis, warranting a summary of its underlying mechanisms and management.
This review provides a comprehensive overview of the pathophysiology of hypertriglyceridemia and highlights emerging therapies targeting specific molecular pathways to reduce cardiovascular and pancreatitis risk.
Updates clinicians on hypertriglyceridemia mechanisms and therapies; leaves open validation of emerging targets in practice.
Hypertriglyceridemia (HTG) is a common metabolic disorder with both genetic and lifestyle factors playing significant roles in its pathophysiology. HTG poses a risk for the development of cardiovascular disease (CVD) in the population at large and for pancreatitis in about two percent of individuals with extremely high levels of triglycerides (TG). This manuscript summarizes the mechanisms underlying the development of HTG as well as its management, including emerging therapies targeted at specific molecular pathways.
No takes yet. Share an insight, caveat, or question.
Santos‐Báez et al. (2020) conducted a review in Hypertriglyceridemia. This review summarizes the mechanisms underlying the development of hypertriglyceridemia and its management, including emerging therapies targeted at specific molecular pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: